Halozyme Therapeutics (HALO) News Today

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $55.12, for a total value of $551,200.00. Following the completion of the sale, the senior vice president now directly owns 168,176 shares in the company, valued at approximately $9,269,861.12. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CFO Nicole Labrosse sold 5,000 shares of the business's stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total value of $269,650.00. Following the transaction, the chief financial officer now owns 15,480 shares in the company, valued at $834,836.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Halozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High After Analyst Upgrade

Edgestream Partners L.P. boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 354.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 65,306 shares of the biopharmaceutical company's stock aft

The Goldman Sachs Group raised their target price on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a "neutral" rating in a research note on Monday.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy rec

Mizuho Markets Americas LLC raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 456,636 shares of the biopha

Scout Investments Inc. reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.0% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 245,861 shares of the biopharmaceutical company's stock after selling 15,622 shares during t

TD Asset Management Inc increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,541,266 shares of the biopharmaceutical comp

Halozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year High at $54.92

HC Wainwright restated a "buy" rating and set a $65.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday.

Tectonic Advisors LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 18,241 shares of the biopharmaceutical company's stock, valued at app

Duality Advisers LP lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 50.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,094 shares of the biopharmaceutical company's

BI Asset Management Fondsmaeglerselskab A S decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 88.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,577 shares of

Halozyme Therapeutics (NASDAQ:HALO) Reaches New 1-Year High at $54.14

Allspring Global Investments Holdings LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 696,127 shares of the biopharmac

Norden Group LLC lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1,817.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 167,284 shares of the biopharmaceutical company'

Hodges Capital Management Inc. lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 61.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 317,045 shares of the biopharmaceutic

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has earned an average rating of "Moderate Buy" from the eight research firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy re

Vanguard Group Inc. grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,259,514 shares of the biopharmaceutical comp

Congress Asset Management Co. MA boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 407,867 shares of the biopharmaceutical company's stock after acquiring

Los Angeles Capital Management LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 17.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 121,000 shares of the biopharm

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 105,000 shares of the biopharma

Virtu Financial LLC acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,421 shares of the biopha

Congress Asset Management Co. MA grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 15.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 351,076 shares of the biopharmaceutical company's stock after purchas

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Matthew L. Posard sold 10,000 shares of the company's stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 109,755 shares in the company, valued at $5,488,847.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Zacks Research dropped their Q2 2024 earnings per share estimates for Halozyme Therapeutics in a research note issued on Monday, June 10th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical

First Light Asset Management LLC decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 57.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 134,050 shares of the biopharmaceutical company's stoc

Prudential PLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,773 shares of the b

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Leerink Partnrs raised their Q2 2024 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued on Friday, June 7th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutic